ditto. the near term sell-off and market dis-appointment has been the extension by Lewin of the feasibility period before Lewin takes HGRD's product and private labels it to their extensive large employer client base.
that extension definitely put a damper on both revenue and earnings forcasts, but even with the Lewin hedge, HGRD seems to be making progress on their plan to position themselves as the JD Power equivalent in the health care quality ratings business.
The Willis deal is a big one and will no doubt bolster revenue/earnings impact.
this is a company with very little analyst coverage and therefore following. their conference calls while positive have consistently witnessed little if any institutional following. defintely still under the radar, IMO.
in2
News 
Market Data 
Discover 
